Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: week 104 results from the SUNSHINE and SUNRISE extension trial
British Journal of Dermatology · 2025
DOI: 10.1093/bjd/ljae469 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Dermatology, 2025. Verfasst von Alexa B Kimball und 16 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Medical School and Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deacone…. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa, Dermatologic Agents, Antibodies, Monoclonal. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
The SUNSHINE and SUNRISE phase III trials demonstrated sustained clinical efficacy of secukinumab in patients with moderate-to-severe hidradenitis suppurativa (HS) through 52 weeks. Patients completing the core trials could enter a 4-year extension trial.
Objectives
To evaluate the long-term efficacy, safety/tolerability and maintenance of clinical response to secukinumab through week 104 in the extension trial.
Methods
Patients with a hidradenitis suppurativa (HS) clinical response (HiSCR) at week 52 of the core trials (extension trial baseline visit) entered a randomized withdrawal period. HiSCR responders receiving subcutaneous secukinumab 300 mg every 2 or 4 weeks (SECQ2W/SECQ4W) through week 52 in the core trials were randomized 2 : 1 to continue secukinumab (SECQ2W-R-Q2W or SECQ4W-R-Q4W) or receive placebo (SECQ2W-R-PBO or SECQ4W-R-PBO) through week 104. The primary endpoint was time to loss of response (LOR; newly defined for this trial) through week 104 in week 52 HiSCR responders (SECQ2W-R-Q2W vs. SECQ2W-R-PBO and SECQ4W-R-Q4W vs. SECQ4W-R-PBO). Time to LOR was tested at 1.25% (one-sided) for each comparison (one-sided familywise alpha of 2.5%) through week 104. If LOR was met, patients could remain in the trial on open-label secukinumab treatment. Additional endpoints included safety and HiSCR. The trial was registered with ClinicalTrials.gov (NCT04179175).
Results
Overall, 84.3% of patients who completed the core trials entered the extension trial; 55.9% were week 52 HiSCR responders. The primary endpoint was not met for either secukinumab dosing regimen. The estimated risk reduction for LOR was 13% (SECQ2W-R-Q2W vs. SECQ2W-R-PBO; one-sided P = 0.25) and 30% (SECQ4W-R-Q4W vs. SECQ4W-R-PBO; one-sided P = 0.04). The median time to LOR was numerically longer in the secukinumab arms vs. placebo {SECQ2W-R-Q2W [283 days; 95% confidence interval (CI) 176, –] vs. SECQ2W-R-PBO [239 days; 95% CI 120, –]; SECQ4W-R-Q4W [365 days 95% CI 225, –] vs. SECQ4W-R-PBO [171 days; 95% CI 113–337]}. In week 52 HiSCR responders reporting LOR, 44% (SECQ2W-R-Q2W), 58% (SECQ2W-R-PBO), 40% (SECQ4W-R-Q4W) and 34% (SECQ4W-R-PBO) were achieving HiSCR at the time of LOR. Overall, the safety of secukinumab was consistent with the core trials.
Conclusions
The primary endpoint of this trial was not met. HiSCR was maintained in many patients at the time of LOR. The safety of secukinumab was consistent with the previously characterized safety profile in the core trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Harvard Medical School and Clinical Laboratory for Epidemiology and Applied Research in Skin (CLEARS), Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
- International Centre for Hidradenitis Suppurativa/Acne Inversa (ICH), Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, Bochum, Germany.
- Chris Hani Baragwanath Academic Hospital, Soweto, Gauteng, South Africa.
- 4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
- Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA.
- Department of Dermatology, Zealand University Hospital, Roskilde, Denmark.
ORCID-Profile: Evangelos J Giamarellos-Bourboulis
Zitieren
APA
Kimball, A. B., Bechara, F. G., Badat, A., Giamarellos-Bourboulis, E. J., Gottlieb, A. B., Jemec, G. B. E., Reguiai, Z., Villani, A. P., Alarcon, I., Bansal, A., Gasperoni, F., Martin, R., Paguet, B., Uhlmann, L., Zouater, H., Ravichandran, S., & Alavi, A. (2025). Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: week 104 results from the SUNSHINE and SUNRISE extension trial. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljae469
Vancouver
Kimball AB, Bechara FG, Badat A, Giamarellos-Bourboulis EJ, Gottlieb AB, Jemec GBE, et al. Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: week 104 results from the SUNSHINE and SUNRISE extension trial. British Journal of Dermatology. 2025. doi:10.1093/bjd/ljae469
BibTeX
@article{Kimball2025,
author = {Kimball, Alexa B and Bechara, Falk G and Badat, Aysha and Giamarellos-Bourboulis, Evangelos J and Gottlieb, Alice B and Jemec, Gregor B E and Reguiai, Ziad and Villani, Axel P and Alarcon, Ivette and Bansal, Amita and Gasperoni, Francesca and Martin, Ruvie and Paguet, Bertrand and Uhlmann, Lorenz and Zouater, Hichem and Ravichandran, Shoba and Alavi, Afsaneh},
title = {Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: week 104 results from the SUNSHINE and SUNRISE extension trial},
journal = {British Journal of Dermatology},
year = {2025},
doi = {10.1093/bjd/ljae469}
}
EUVIMED